Leukemia: Symptoms, Types

Brief overview Symptoms: Fatigue and exhaustion, decreased performance, skin pallor, tendency to bleed and bruise (hematoma), tendency to infection, fever of unknown cause, weight loss, night sweats. Common forms: Acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), chronic lymphocytic leukemia (CLL; actually a form of lymphoma) Treatment: Depending on the type … Leukemia: Symptoms, Types

Obinutuzumab

Products Obinutuzumab is commercially available as a concentrate for the preparation of an infusion solution (Gazyvaro). It has been approved in many countries since 2014. Structure and properties Obinutuzumab is a recombinant, monoclonal, and humanized type II antibody against CD20 of the IgG1 isotype. It has a molecular weight of approximately 150 kDa. Obinutuzumab is … Obinutuzumab

Ofatumumab

Products Ofatumumab was approved in 2009 as a concentrate for the preparation of an infusion solution for leukemia treatment (Arzerra). In 2020, a solution for injection was approved in the United States for MS treatment (Kesimpta). Structure and properties Ofatumumab is a human IgG1 monoclonal antibody produced by biotechnological methods. It has a molecular mass … Ofatumumab

Cancer: the Dreaded Diseases

Cancer is a collective term for a wide variety of malignant diseases that can affect virtually all human organs. In Germany, colorectal cancer as well as lung cancer are particularly common – along with breast cancer as the most common cancer in women and prostate cancer as the most common cancer in men. In the … Cancer: the Dreaded Diseases

Dasatinib

Products Dasatinib is commercially available in the form of film-coated tablets (Sprycel). It has been approved in many countries since 2007. Generic versions were registered in 2020. Structure and properties Dasatinib (C22H26ClN7O2S, Mr = 488.0 g/mol) exists as a white powder that is insoluble in water. It is an aminopyrimidine derivative. Effects Dasatinib (ATC L01XE06) … Dasatinib

Alemtuzumab

Products Alemtuzumab is commercially available as a concentrate for the preparation of an infusion solution (Lemtrada). It was approved in 2014. Alemtuzumab was originally approved for leukemia treatment and marketed as MabCampath (approved in 2001). Structure and properties Alemtuzumab is a humanized IgG1 kappa monoclonal antibody to CD52 produced by biotechnological methods. It has a … Alemtuzumab

Daunorubicin

Structure and properties Daunorubicin (C27H29NO10, Mr = 527.5 g/mol) Effects Daunorubicin (ATC L01DB02) is a cytotoxic anthracycline antibiotic. It is isolated from cultures of various Streptomyces strains. By intercalation into DNA, it inhibits topoisomerase II and thereby nucleic acid and protein synthesis and cell division. Indications Leukemia Hodgkin’s disease Neuroblastoma